Selection of imaging biomarkers and construction of evaluation methods for the efficacy evaluation of neoadjuvant therapy in locally advanced prostate cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300077562

Enrollment

Unknown

Registered

2023-11-13

Start date

2023-11-20

Completion date

Unknown

Last updated

2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proatste Cancer

Interventions

Gold Standard:Pathological Diagnosis of Prostate and Lymph Node Specimens after Radical Prostatectomy

Index test:The Accuracy of PSMA PET/CT and MRI Diagnostics

Eligibility

Sex/Gender

Male

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Age = 18 and = 80 years old, confirmed by biopsy as prostate cancer; ? After comprehensive clinical evaluation, it belongs to the stage of local progression and has been determined to use a sequential RP treatment regimen with neoadjuvant therapy.

Exclusion criteria

Exclusion criteria: ? Received radiation therapy, ablation therapy, embolization, chemotherapy, or immunotherapy before RP treatment; ? In the acute infection and fever period; ? Concomitant with other malignant tumors; ? Those who cannot complete PSMA PET/CT or MPMRI examinations; ? Severe adverse reactions to PET imaging agents.

Design outcomes

Primary

Measure	Time frame
SUVmax of prostate cancer related lesions;ROC;area under curve,AUC;	—

Countries

China

Contacts

Public ContactZHU HUI

Beijing Hospital

pkuzhu@163.com+86 138 1113 5750

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026